Evidenced, a VC firm focused on health technology, has closed its first fund with $24 million in commitments. The fund will back early-stage companies navigating regulatory challenges, with notable investments already made in Floreo and Ilant Health.
TL;DR
- Evidenced raises $24M to invest in regulation-conscious health tech startups.
- Trase secures $107M to scale AI agents for high-stakes environments like healthcare.
- Health tech funding rounds highlight AI's growing role in transforming healthcare delivery and administration.
What happened
Evidenced, founded in 2022 by Bryan Sivak and Sean Glass, has closed its Fund I with $24 million in commitments. Investors include the Rockefeller Foundation, the RockCreek Group, and Colibri Equity Ventures, alongside undisclosed individual LPs. The firm focuses on health technology startups that leverage regulatory and policy changes as catalysts for market opportunities. Evidenced has already invested in companies like Floreo, Ilant Health, Koda Health, and Photon Health, with a portfolio described in more depth on their Substack.
Trase, an AI solutions platform offering operating systems and agents for high-stakes environments, has secured $107 million in seed funding. The round was led by ARCH Venture Partners, with participation from Red Cell Partners and others. Trase's technology is being used by Duke University Health System to automate administrative tasks, such as fax routing, and manage chronic conditions. The funding will be used to expand Trase's go-to-market team and continue developing its operating systems.
Why it matters
For developers and startups, Evidenced's focus on regulation-conscious health tech presents a unique opportunity to build solutions that navigate complex regulatory landscapes. The firm's investments in early-stage companies highlight the growing interest in health tech startups that can leverage policy changes to create market opportunities.
Trase's significant seed funding round underscores the growing demand for AI solutions in healthcare administration. The company's success in automating tasks at Duke University Health System demonstrates the potential for AI agents to improve efficiency and reduce costs in high-stakes environments. For investors, Trase's funding round represents a significant bet on the future of AI in healthcare.
Key facts
- Evidenced Fund I: $24 million
- Evidenced investors: Rockefeller Foundation, the RockCreek Group, Colibri Equity Ventures, and undisclosed individual LPs
- Evidenced portfolio companies: Floreo, Ilant Health, Koda Health, Photon Health
- Trase seed funding: $107 million
- Trase lead investor: ARCH Venture Partners
- Trase other investors: Red Cell Partners and others
- Trase's fax routing agent at Duke University Health System: unlocked $285,450 in annual staff capacity
- Trase's intended use of funds: expand go-to-market team and continue developing operating systems
Context
The health tech and digital health industries have seen a surge in venture capital investment in recent years. According to Fierce Healthcare, the sector has attracted significant attention from investors looking to capitalize on the growing demand for innovative healthcare solutions. Evidenced and Trase are among the latest companies to secure substantial funding rounds, highlighting the competitive landscape and the potential for AI to transform healthcare delivery and administration.
The growing interest in health tech startups that can navigate regulatory challenges is a testament to the complex landscape of healthcare policy. Companies that can leverage these policies to create market opportunities are likely to attract significant investment and attention from investors. As the healthcare industry continues to evolve, the role of AI and other innovative technologies will become increasingly important in shaping the future of healthcare delivery.